ATE418964T1 - Ophthalmische öl-in-wasser-emulsion mit stabilem positivem zeta-potential - Google Patents

Ophthalmische öl-in-wasser-emulsion mit stabilem positivem zeta-potential

Info

Publication number
ATE418964T1
ATE418964T1 AT05795930T AT05795930T ATE418964T1 AT E418964 T1 ATE418964 T1 AT E418964T1 AT 05795930 T AT05795930 T AT 05795930T AT 05795930 T AT05795930 T AT 05795930T AT E418964 T1 ATE418964 T1 AT E418964T1
Authority
AT
Austria
Prior art keywords
water emulsion
zeta potential
positive zeta
stable positive
ophthalmic oil
Prior art date
Application number
AT05795930T
Other languages
English (en)
Inventor
Severine Bague
Betty Philips
Laura Rabinovich-Guilatt
Gregory Lambert
Jean-Sebastien Garrigue
Original Assignee
Novagali Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34931510&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE418964(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novagali Pharma Sa filed Critical Novagali Pharma Sa
Application granted granted Critical
Publication of ATE418964T1 publication Critical patent/ATE418964T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Colloid Chemistry (AREA)
  • Cosmetics (AREA)
AT05795930T 2004-11-09 2005-10-10 Ophthalmische öl-in-wasser-emulsion mit stabilem positivem zeta-potential ATE418964T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04292645A EP1655021B1 (de) 2004-11-09 2004-11-09 Öl-in-Wasser-Emulsion mit niedriger Konzentration des kationischen Mittels und positivem Zetapotential
US10/991,346 US8298568B2 (en) 2004-11-09 2004-11-18 Oil-in-water type emulsion with low concentration of cationic agent and positive zeta potential

Publications (1)

Publication Number Publication Date
ATE418964T1 true ATE418964T1 (de) 2009-01-15

Family

ID=34931510

Family Applications (5)

Application Number Title Priority Date Filing Date
AT04292645T ATE412400T1 (de) 2004-11-09 2004-11-09 Öl-in-wasser-emulsion mit niedriger konzentration des kationischen mittels und positivem zetapotential
AT05795930T ATE418964T1 (de) 2004-11-09 2005-10-10 Ophthalmische öl-in-wasser-emulsion mit stabilem positivem zeta-potential
AT05802097T ATE412401T1 (de) 2004-11-09 2005-10-10 Ophthalmische emulsion mit einem immunosuppressiven mittel
AT05800012T ATE415942T1 (de) 2004-11-09 2005-10-10 Prostaglandine enthaltende ophthalmische emulsionen
AT08102553T ATE498392T1 (de) 2004-11-09 2005-10-10 Ophthalmische emulsionen mit einem immunsuppressiven mittel

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT04292645T ATE412400T1 (de) 2004-11-09 2004-11-09 Öl-in-wasser-emulsion mit niedriger konzentration des kationischen mittels und positivem zetapotential

Family Applications After (3)

Application Number Title Priority Date Filing Date
AT05802097T ATE412401T1 (de) 2004-11-09 2005-10-10 Ophthalmische emulsion mit einem immunosuppressiven mittel
AT05800012T ATE415942T1 (de) 2004-11-09 2005-10-10 Prostaglandine enthaltende ophthalmische emulsionen
AT08102553T ATE498392T1 (de) 2004-11-09 2005-10-10 Ophthalmische emulsionen mit einem immunsuppressiven mittel

Country Status (14)

Country Link
US (5) US8298568B2 (de)
EP (1) EP1655021B1 (de)
JP (3) JP5587936B2 (de)
CN (3) CN101056615B (de)
AT (5) ATE412400T1 (de)
DE (5) DE602004017477D1 (de)
DK (1) DK1809237T3 (de)
ES (4) ES2314354T3 (de)
HK (2) HK1107938A1 (de)
IL (3) IL181446A (de)
MX (2) MX2007005545A (de)
NZ (1) NZ554929A (de)
PT (2) PT1809237E (de)
ZA (1) ZA200703751B (de)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767216B2 (en) 1999-04-28 2010-08-03 The Regents Of The University Of Michigan Antimicrobial compositions and methods of use
US7655252B2 (en) 1999-04-28 2010-02-02 The Regents Of The University Of Michigan Antimicrobial nanoemulsion compositions and methods
US8236335B2 (en) 1999-04-28 2012-08-07 The Regents Of The University Of Michigan Antimicrobial nanoemulsion compositions and methods
US20050208083A1 (en) 2003-06-04 2005-09-22 Nanobio Corporation Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof
ES2314354T3 (es) * 2004-11-09 2009-03-16 Novagali Pharma S.A. Emulsion de tipo aceite en agua con baja concentracion de agente cationico y potencial zeta positivo.
US20070054834A1 (en) * 2005-04-11 2007-03-08 Nanobio Corporation Quaternary ammonium halides for treatment of infectious conditions
US7297679B2 (en) * 2005-07-13 2007-11-20 Allergan, Inc. Cyclosporin compositions
JP2009504805A (ja) * 2005-08-09 2009-02-05 ナノバイオ コーポレーション 抗炎症活性を有するナノエマルジョン組成物
US7797337B2 (en) * 2005-09-29 2010-09-14 Scenera Technologies, Llc Methods, systems, and computer program products for automatically associating data with a resource as metadata based on a characteristic of the resource
US11311477B2 (en) 2006-03-07 2022-04-26 Sgn Nanopharma Inc. Ophthalmic preparations
US10137083B2 (en) 2006-03-07 2018-11-27 SGN Nanopharma Inc Ophthalmic preparations
US20070264349A1 (en) * 2006-03-07 2007-11-15 Novavax, Inc. Nano-structured compositions and methods of making and using the same
WO2007111806A2 (en) 2006-03-23 2007-10-04 Massachusetts Eye And Ear Infirmary Cyclopentane heptanoic acid compounds for reducing body fat
SI1891939T1 (sl) * 2006-07-28 2013-11-29 Novagali Pharma S.A. Sestave vsebujoče kvaternarne amonijeve spojine
US9132071B2 (en) * 2006-07-28 2015-09-15 Santen Sas Compositions containing quaternary ammonium compounds
AU2014201978B2 (en) * 2006-07-28 2016-03-10 Santen Sas Compositions containing quaternary ammonium compounds
WO2008035246A2 (en) 2006-07-28 2008-03-27 Novagali Pharma Sa Compositions containing quaternary ammonium compounds
US20080026013A1 (en) * 2006-07-28 2008-01-31 Laura Rabinovich-Guilatt Compositions containing quaternary ammonium compounds
EP2444829A1 (de) 2006-09-14 2012-04-25 Carl Zeiss SMT GmbH Optische Elementeinheit und Verfahren zum Stützen eines optischen Elements
EP1938801A1 (de) * 2006-12-22 2008-07-02 Biofrontera Bioscience GmbH Nanoemulsion
EP1985298A1 (de) 2007-04-24 2008-10-29 Azad Pharma AG Prostaglandinhaltige Öl-in-Wasser-Emulsionen für das Auge
EP2152304B1 (de) 2007-05-02 2018-08-22 The Regents of the University of Michigan Therapeutische zusammensetzungen in nanoemulsionsform und anwendungsverfahren dafür
US9125807B2 (en) 2007-07-09 2015-09-08 Incept Llc Adhesive hydrogels for ophthalmic drug delivery
US8512687B2 (en) * 2007-07-09 2013-08-20 Novagali Pharma Sa Oil in water emulsion comprising NSAIDs and quaternary ammonium halides
US20090018057A1 (en) * 2007-07-09 2009-01-15 Gregory Lambert OIL IN WATER EMULSION COMPRISING NSAIDs AND QUATERNARY AMMONIUM HALIDES
NZ584555A (en) * 2007-10-16 2012-03-30 Sun Pharma Advanced Res Co Ltd Stabilised ophthalmic composition comprising a prostaglandin and a polyethylene glycol hydroxystearate such as solutol hs 15
US7834172B2 (en) * 2007-11-14 2010-11-16 Novagali Pharma Sa Composition comprising at least one nucleosidic moiety as a therapeutic agent, and CKC
WO2009063081A2 (en) * 2007-11-14 2009-05-22 Novagali Pharma Sa Composition comprising at least one nucleosidic moiety as a therapeutic agent, and ckc.
EP2077105A1 (de) * 2008-01-02 2009-07-08 Novagali Pharma SA Ophthalmische mizellare Zusammensetzung mit erhöhter Stabilität
EP2077104A1 (de) * 2008-01-02 2009-07-08 Novagali Pharma SA Mizellare Zusammensetzungen mit ophtalmischen Anwendungen
EP2127638A1 (de) * 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Verfahren und Zusammensetzung zur Behandlung von Augenhochdruck und Glaukom
WO2010027040A1 (ja) * 2008-09-04 2010-03-11 参天製薬株式会社 １５，１５－ジフルオロプロスタグランジンＦ2α誘導体を有効成分として含有する毛髪成長促進剤
PL2331128T3 (pl) * 2008-09-05 2014-06-30 Ceva Sante Animale Sa Kompozycja zawierająca chitozan do doocznego podawania szczepionki (szczepionek) ptakom
WO2010057197A1 (en) 2008-11-17 2010-05-20 The Regents Of The University Of Michigan Cancer vaccine compositions and methods of using the same
AU2010213612B2 (en) 2009-02-12 2015-04-30 Incept, Llc Drug delivery through hydrogel plugs
EP2228058A1 (de) 2009-03-04 2010-09-15 Novagali Pharma S.A. Anionische Öl-in-Wasser-Emulsion mit Prostaglandinen und Verwendungen dafür
EP2228057A1 (de) * 2009-03-04 2010-09-15 Novagali Pharma S.A. Kationische Öl-in-Wasser-Emulsionen mit Prostaglandinen und Verwendungen dafür
US8299079B2 (en) 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
WO2010135731A1 (en) * 2009-05-22 2010-11-25 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
EP2498784A2 (de) * 2009-11-09 2012-09-19 Allergan, Inc. Zusammensetzungen zur förderung des haarwuchses
EP2389939A1 (de) * 2010-05-28 2011-11-30 Novagali Pharma S.A. Verwendung von Prostaglandinen F2alpha und Analoga zur Heilung von Horn- und Bindehautläsionen
EA201390120A3 (ru) 2010-07-15 2013-09-30 Коринтиан Офтэлмик, Инк. Доставка офтальмологических лекарственных средств
US10154923B2 (en) 2010-07-15 2018-12-18 Eyenovia, Inc. Drop generating device
US10272040B2 (en) 2010-08-12 2019-04-30 Nanyang Technological University Liposomal formulation for ocular drug delivery
US8961501B2 (en) 2010-09-17 2015-02-24 Incept, Llc Method for applying flowable hydrogels to a cornea
CA2824317C (en) 2011-01-19 2014-12-16 Terakine Therapeutics, Inc. Uses of certain f-series prostaglandin analogs for treating diabetes and dyslipidemia
DK2667877T3 (en) 2011-01-26 2018-06-14 Allergan Inc ANDROGEN COMPOSITION FOR TREATMENT OF Ophthalmic condition
WO2013011511A1 (en) 2011-07-18 2013-01-24 Mor Research Applications Ltd. A device for adjusting the intraocular pressure
US10226417B2 (en) 2011-09-16 2019-03-12 Peter Jarrett Drug delivery systems and applications
ES2791751T3 (es) 2011-11-15 2020-11-05 Allergan Inc Suspensiones de forma 2 de ciclosporina A
BR112014011733A2 (pt) 2011-11-15 2017-05-09 Allergan Inc suspensões autoclaváveis da forma 2 de ciclosporina a
CA2858161C (en) 2011-12-05 2020-03-10 Incept, Llc Medical organogel processes and compositions
US8426471B1 (en) * 2011-12-19 2013-04-23 Topokine Therapeutics, Inc. Methods and compositions for reducing body fat and adipocytes
EP2821467B1 (de) * 2012-02-24 2018-02-14 Fain-Biomedical Inc. Verwendung eines schmierfähigkeits-regulierungsmittels für siliconoberflächen
HUE062145T2 (hu) 2012-08-24 2023-10-28 Sun Pharmaceutical Ind Ltd Polioxil lipid vagy polioxil zsírsav szemészeti készítménye és szemészeti állapotok kezelése
SG11201501039WA (en) * 2012-09-06 2015-03-30 Univ Nanyang Tech Hyaluronic acid-based drug delivery systems
MX2015006390A (es) 2012-11-21 2015-08-05 Topokine Therapeutics Inc Metodos y composiciones para incrementar localmente la grasa corporal.
ES2797376T3 (es) 2013-01-24 2020-12-02 Palvella Therapeutics Inc Composiciones para la administración transdérmica de inhibidores de mTOR
ES2930433T3 (es) 2013-03-05 2022-12-12 Univ Pittsburgh Commonwealth Sys Higher Education Hidrogel termosensible que contiene micropartículas de polímero para la administración ocular no invasiva de fármaco
EP2974728B1 (de) * 2013-03-13 2020-05-06 Santen Pharmaceutical Co., Ltd Therapeutikum für meibomdrüsendysfunktion
US20140275261A1 (en) * 2013-03-15 2014-09-18 Dr. Reddy's Laboratories, Inc. Diclofenac parenteral compositions
RU2513597C1 (ru) * 2013-04-17 2014-04-20 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт глазных болезней" Российской академии медицинских наук (ФГБУ "НИИГБ" РАМН) Способ лечения воспалительных состояний переднего отрезка глаза
NO2753788T3 (de) 2013-05-10 2018-06-16
US9820993B2 (en) 2013-05-15 2017-11-21 Topokine Therapeutics, Inc. Methods and compositions for topical delivery of prostaglandins to subcutaneous fat
WO2014207769A1 (en) 2013-06-27 2014-12-31 Mylan Laboratories Ltd Process for the preparation of nepafenac
US9956195B2 (en) 2014-01-07 2018-05-01 Nanyang Technological University Stable liposomal formulations for ocular drug delivery
EP3104840B8 (de) 2014-02-11 2019-07-10 Latitude Pharmaceuticals Inc. Parenterale zusammensetzungen von celecoxib
JP2017506671A (ja) 2014-02-14 2017-03-09 ホアン，ジンジュン ナノエマルジョン送達系の組成物
WO2015189387A1 (en) * 2014-06-13 2015-12-17 Sanofi Nanocapsular formulation of active pharmaceutical ingredients
US10188661B2 (en) 2014-06-27 2019-01-29 Topokine Therapeutics, Inc. Topical dosage regimen
EP3233174B1 (de) * 2014-12-19 2021-03-31 Kemin Industries, Inc. Intraokulare abgabe bioaktiver moleküle mittels iontophorese
US11324800B2 (en) 2015-01-15 2022-05-10 Wellspring Ophthalmics, Inc. Aqueous suspensions of cyclosporin
US20200237859A1 (en) 2019-01-25 2020-07-30 Newport Research, Inc. Aqueous suspensions of cyclosporin
EP3253372B8 (de) * 2015-02-06 2022-06-22 Woodstock Sterile Solutions, Inc. Herstellung einer öl-in-wasser-emulsion für polymerstabilisierte pharmazeutische formulierungen
CN106176600A (zh) * 2015-05-07 2016-12-07 上海现代药物制剂工程研究中心有限公司 一种前列地尔冻干微乳剂、原料组合物及其制备方法
WO2016182926A1 (en) * 2015-05-08 2016-11-17 Affinsci Inc. Preparation of nanoemulsions
AU2016351588A1 (en) 2015-11-10 2018-05-24 Sun Pharma Global Fze Topical formulations and uses thereof
BR112018067946A8 (pt) 2016-02-29 2022-11-08 Sun Pharma Global Fze Formulações tópicas contendo ciclosporina e usos das mesmas
JP6906899B2 (ja) * 2016-03-30 2021-07-21 小林製薬株式会社 乳化組成物
US11285274B2 (en) 2016-05-03 2022-03-29 Pneuma Respiratory, Inc. Methods for the systemic delivery of therapeutic agents to the pulmonary system using a droplet delivery device
WO2017192773A1 (en) 2016-05-03 2017-11-09 Pneuma Respiratory, Inc. Methods for treatment of pulmonary lung diseases with improved therapeutic efficacy and improved dose efficiency
EP3452152A4 (de) 2016-05-03 2020-01-01 Pneuma Respiratory, Inc. Verfahren zur erzeugung und abgabe von tröpfchen an das lungensystem unter verwendung einer tröpfchenabgabevorrichtung
WO2017192782A1 (en) 2016-05-03 2017-11-09 Pneuma Respiratory, Inc. Systems and methods comprising a droplet delivery device and a breathing assist device for therapeutic treatment
KR102122887B1 (ko) 2016-05-03 2020-06-16 뉴마 레스퍼러토리 인코포레이티드 유체들의 폐기관계로의 전달을 위한 액적 전달 디바이스 및 사용 방법
US11395853B2 (en) 2016-06-23 2022-07-26 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Biomimetic drug delivery of an immunomodulatory agent for the treatment of ocular conditions
PL3266446T3 (pl) * 2016-07-07 2019-05-31 Salvat Lab Sa Kompozycja oftalmiczna zawierająca olej rycynowy i trójgliceryd o średniej długości łańcucha
CN106782348A (zh) * 2017-01-04 2017-05-31 深圳市华星光电技术有限公司 一种led背光驱动电路及液晶显示器
US10722499B2 (en) 2017-01-06 2020-07-28 Palvella Therapeutics, Inc. Anyhydrous compositions of mTOR inhibitors and methods of use
CA3064005C (en) 2017-05-19 2023-03-07 Pneuma Respiratory, Inc. Dry powder delivery device and methods of use
CA3065474A1 (en) * 2017-05-30 2018-12-06 Eximore Ltd. Compositions and methods for treating dry eye syndrome delivering antibiotic macrolide
CN115300226A (zh) 2017-06-10 2022-11-08 艾诺维亚股份有限公司 用于将一体积的流体输送到眼睛的设备
CN111526914A (zh) 2017-10-04 2020-08-11 精呼吸股份有限公司 电子呼吸致动式直线型液滴输送装置及其使用方法
EP4344719A3 (de) 2017-10-17 2024-06-05 Pneuma Respiratory, Inc. Nasale arzneimittelabgabevorrichtung und verwendungsverfahren
US11253480B2 (en) 2017-10-30 2022-02-22 University of Pittsburgh—of the Commonwealth System of Higher Education Treatment of ocular conditions utilizing a histone/protein deacetylase inhibitor
US11771852B2 (en) 2017-11-08 2023-10-03 Pneuma Respiratory, Inc. Electronic breath actuated in-line droplet delivery device with small volume ampoule and methods of use
CA3092016A1 (en) * 2018-02-26 2020-08-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Drug delivery systems
EP3817743A4 (de) 2018-07-02 2022-07-06 Palvella Therapeutics, Inc. Wasserfreie zusammensetzungen von mtor-hemmern und verfahren zur verwendung
CN109010268B (zh) * 2018-09-28 2020-07-10 湖北远大天天明制药有限公司 一种提高氯霉素稳定性的眼用组合物及其制备方法
CA3119037A1 (en) 2018-12-11 2020-06-18 Disruption Labs Inc. Compositions for the delivery of therapeutic agents and methods of use and making thereof
CN110237233B (zh) * 2019-07-30 2021-01-15 沈阳兴齐眼药股份有限公司 一种含有环孢素的眼用药物组合物、其制备方法及用途
WO2021113637A1 (en) * 2019-12-04 2021-06-10 Restore Vision, Llc. Ophthalmic formulations for the treatment of presbyopia
US20230210771A1 (en) * 2020-06-10 2023-07-06 Disruption Labs Inc. Compositions for the delivery of therapeutic agents and methods of use and making thereof
KR20240037245A (ko) 2021-06-22 2024-03-21 뉴마 레스퍼러토리 인코포레이티드 푸시 이젝션에 의한 액적 전달 장치
CN113577024B (zh) * 2021-08-20 2023-05-05 山西利普达医药科技有限公司 一种眼用组合物及其制备方法和应用
CN116407499B (zh) * 2021-12-29 2024-10-25 辅必成（上海）医药科技有限公司 一种他克莫司眼用乳剂及其制备方法

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599353A (en) * 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
JPH0818989B2 (ja) * 1984-01-12 1996-02-28 株式会社ミドリ十字 脂肪乳剤中のプロスタグランジンの安定化方法
US4839342A (en) 1987-09-03 1989-06-13 University Of Georgia Research Foundation, Inc. Method of increasing tear production by topical administration of cyclosporin
JP2602964B2 (ja) 1989-10-16 1997-04-23 裕 水島 プロスタグランジン類縁体およびその脂肪乳剤
IL101241A (en) * 1992-03-16 1997-11-20 Yissum Res Dev Co Pharmaceutical or cosmetic composition comprising stabilized oil-in-water type emulsion as carrier
IL103907A0 (en) * 1992-11-27 1993-04-04 Pharmos Corp Ophthalmic compositions
CA2142103C (en) * 1992-08-28 2003-07-08 Haim Aviv Submicron emulsions as ocular drug delivery vehicles
US5688819A (en) * 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
JP3551977B2 (ja) * 1993-04-08 2004-08-11 ライオン株式会社 安定なビタミンａ類及びビタミンｅ類可溶化点眼剤
DE69411816T2 (de) * 1993-06-25 1998-12-03 Alcon Cusi, S.A., El Masnou, Barcelona Neue Verwendung von polymeren Membranen zum Ausgeben von pharmazeutischen Lösungen, die quarternäre, als Konserviermittel dienende Ammoniumverbindungen enthalten und entsprechender Dosierbehälter
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
JP2936209B2 (ja) * 1994-06-01 1999-08-23 ユーハン コーポレーション サイクロスポリン含有組成物およびその製造方法
ES2094688B1 (es) * 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
US5631287A (en) * 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US6011062A (en) * 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US5767153A (en) * 1995-06-07 1998-06-16 Insite Vision Incorporated Sustained release emulsions
DE69807281T2 (de) 1997-05-14 2003-04-17 Mitsubishi Chemical Corp., Tokio/Tokyo Difluprednat enthaltende Zusammensetzungen
JP3410364B2 (ja) * 1997-05-14 2003-05-26 千寿製薬株式会社 ジフルプレドナート含有組成物
US6066671A (en) * 1997-12-19 2000-05-23 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides
US6225348B1 (en) * 1998-08-20 2001-05-01 Alfred W. Paulsen Method of treating macular degeneration with a prostaglandin derivative
AU2183900A (en) * 1998-12-24 2000-07-31 Alcon Laboratories, Inc. Ep4 receptor agonists for treatment of dry eye
US20020136771A1 (en) * 1998-12-31 2002-09-26 Amitee Cosmetics, Inc. Stabilized ascorbic acid composition
FR2823441B1 (fr) * 2001-04-12 2004-09-10 Thea Lab Composition pharmaceutique a base de macrolides pour application locale en ophtalmologie et son procede de preparation
US20040198829A1 (en) * 2001-04-23 2004-10-07 Sponsel William Eric Prostanoids augment ocular drug penetration
JP2006512401A (ja) * 2001-06-05 2006-04-13 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン ナノエマルジョンワクチン
US6872705B2 (en) * 2001-07-13 2005-03-29 Allergan, Inc. Use of antimicrobial peptides as preservatives in ophthalmic preparations, including solutions, emulsions, and suspensions
CN100335036C (zh) * 2001-11-01 2007-09-05 耶路撒冷希伯来语大学依苏姆研究开发公司 用于干眼症治疗的方法和组合物
US6656460B2 (en) * 2001-11-01 2003-12-02 Yissum Research Development Method and composition for dry eye treatment
KR100446960B1 (ko) 2001-12-04 2004-09-01 김종국 프로스타글란딘 ｅ1을 포함하는 온도감응성 에멀젼 외용제조성물
US20030165545A1 (en) * 2002-01-30 2003-09-04 Allergan, Inc. Ophthalmic compositions including oil-in-water emulsions, and methods for making and using same
US20050124699A1 (en) * 2002-07-02 2005-06-09 Wakamoto Pharmaceutical Co., Ltd. Drugs for treating or preventing disorders of corneal and/or conjunctival epithelial cells
KR101027454B1 (ko) 2002-08-23 2011-04-06 산텐 세이야꾸 가부시키가이샤 라타노프로스트를 유효 성분으로 하는 안정한 점안액
WO2004022063A1 (ja) 2002-09-09 2004-03-18 Santen Pharmaceutical Co., Ltd. ラタノプロストを有効成分とする澄明な点眼液
US20040115234A1 (en) * 2002-09-24 2004-06-17 Gewirtz Joan T. Cosmetic composition
US7074827B2 (en) * 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
JP4361294B2 (ja) * 2003-02-25 2009-11-11 ロート製薬株式会社 ケトチフェン含有組成物
JP4694773B2 (ja) * 2003-06-06 2011-06-08 ロート製薬株式会社 粘膜適用液状組成物
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
JP5382972B2 (ja) * 2003-12-26 2014-01-08 ロート製薬株式会社 粘度低下が防止された組成物
US20050175651A1 (en) * 2004-01-09 2005-08-11 L'oreal Aqueous dispersion of nanocapsules with an oily core
DE602004022523D1 (de) 2004-07-02 2009-09-24 Novagali Pharma Sa Verwendung von Emulsionen zur intra- und periocularen Injection
JP4999304B2 (ja) * 2004-09-27 2012-08-15 ロート製薬株式会社 ヒアルロン酸又はその塩を含有する粘膜適用組成物
WO2006050838A2 (en) * 2004-11-09 2006-05-18 Novagali Pharma Sa Ophthalmic oil-in-water type emulsion with stable positive zeta potential
ES2314354T3 (es) * 2004-11-09 2009-03-16 Novagali Pharma S.A. Emulsion de tipo aceite en agua con baja concentracion de agente cationico y potencial zeta positivo.
US20090169629A1 (en) * 2008-01-02 2009-07-02 Novagali Pharma Sa Micellar compositions with ophthalmic applications
US20090170944A1 (en) * 2008-01-02 2009-07-02 Novagali Pharma Sa Ophthalmic micellar compositions with enhanced stability
CA2725523C (en) * 2008-05-28 2017-01-10 Alcon Research, Ltd. Self-preserved emulsions
EP2228058A1 (de) * 2009-03-04 2010-09-15 Novagali Pharma S.A. Anionische Öl-in-Wasser-Emulsion mit Prostaglandinen und Verwendungen dafür
EP2228057A1 (de) * 2009-03-04 2010-09-15 Novagali Pharma S.A. Kationische Öl-in-Wasser-Emulsionen mit Prostaglandinen und Verwendungen dafür
EP2389939A1 (de) * 2010-05-28 2011-11-30 Novagali Pharma S.A. Verwendung von Prostaglandinen F2alpha und Analoga zur Heilung von Horn- und Bindehautläsionen

Also Published As

Publication number Publication date
CN103356481A (zh) 2013-10-23
ATE412401T1 (de) 2008-11-15
PT1809238E (pt) 2009-02-09
ES2314354T3 (es) 2009-03-16
MX2007003045A (es) 2007-08-02
ATE498392T1 (de) 2011-03-15
ES2317319T3 (es) 2009-04-16
US8298569B2 (en) 2012-10-30
JP2012149102A (ja) 2012-08-09
JP5587936B2 (ja) 2014-09-10
JP5773941B2 (ja) 2015-09-02
ES2320574T3 (es) 2009-05-25
US20060100288A1 (en) 2006-05-11
CN101014317A (zh) 2007-08-08
JP2012162549A (ja) 2012-08-30
US8273362B2 (en) 2012-09-25
HK1112411A1 (en) 2008-09-05
HK1107938A1 (en) 2008-04-25
DE602005010733D1 (de) 2008-12-11
IL181446A (en) 2010-06-16
EP1655021B1 (de) 2008-10-29
DE602005026464D1 (de) 2011-03-31
DK1809237T3 (da) 2009-05-04
US20080107738A1 (en) 2008-05-08
NZ554929A (en) 2010-09-30
IL182897A0 (en) 2007-08-19
DE602004017477D1 (de) 2008-12-11
EP1655021A1 (de) 2006-05-10
CN101056615A (zh) 2007-10-17
DE602005012136D1 (de) 2009-02-12
CN101056615B (zh) 2011-05-11
US20080268020A1 (en) 2008-10-30
US20090028955A1 (en) 2009-01-29
ATE412400T1 (de) 2008-11-15
US20070248645A1 (en) 2007-10-25
MX2007005545A (es) 2007-07-05
PT1809237E (pt) 2009-04-09
IL181446A0 (en) 2007-07-04
JP5894202B2 (ja) 2016-03-23
ES2319129T3 (es) 2009-05-04
IL182897A (en) 2010-12-30
ZA200703751B (en) 2008-08-27
JP2014088450A (ja) 2014-05-15
ATE415942T1 (de) 2008-12-15
CN103356481B (zh) 2017-11-28
US8372434B2 (en) 2013-02-12
DE602005011480D1 (de) 2009-01-15
IL190497A (en) 2012-01-31
IL190497A0 (en) 2008-11-03
US8298568B2 (en) 2012-10-30

Similar Documents

Publication Publication Date Title
ATE418964T1 (de) Ophthalmische öl-in-wasser-emulsion mit stabilem positivem zeta-potential
WO2006050837A3 (en) Ophthalmic emulsions containing an immunosuppressive agent
BRPI0506983A (pt) composições para terapia localizada dos olhos, compreendendo preferencialmente acetonida de triancinolona e ácido hialurÈnico
BRPI0411306A (pt) composições farmacêuticas compreendendo compostos ativos de vitamina d
EA200600877A1 (ru) Наночастицы для доставки лекарств
CY1110264T1 (el) Φαρμακευτικες συνθεσεις που περιλαμβανουν ευαισθητα σε ρη συμπολυμερη τυπου μπλοκ και υδροφοβο φαρμακο
ES2134850T3 (es) Emulsiones farmaceuticas o cosmeticas aceite en agua de particulas cargadas positivamente.
WO2002083097A3 (en) Drug delivery system for hydrophobic drugs
WO2005072709A3 (en) Formulations for poorly soluble drugs
WO2005049091A3 (en) Antibody-targeted nanoparticulate active agent delivery
WO2008070538A3 (en) Micellar nanoparticles comprising botulinum toxin
EA200401252A1 (ru) Микрочастицы лекарственных веществ
DK1553927T3 (da) Gel-stabiliserede, nanopartikulære aktivstof-sammensætninger
WO2004026231A3 (en) Formulation for lipophilic agents
DE60216305D1 (de) Zusammensetzungen zur verabreichung von arzneimittelkombinationen
WO2006039704A3 (en) Pharmaceutical composition and method for treating a joint capsule arthropathy
WO2008067164A3 (en) Solid pharmaceutical dosage formulations
WO2008109385A3 (en) Oral administration of a calcitonin
MA27850A1 (fr) Preparations pharmaceutiques contenant de l'amoxicilline et du clavulanate
BRPI0504082A (pt) emulsões refrescantes medicinais
WO2004071386A3 (en) Compositions comprising microcapsules containing magnetic nanoparticles and biologically active molecules, their preparation and use
WO2006003519A3 (en) Use of emulsions for intra: and periocular injection
DK1275383T3 (da) "Modified release" farmaceutisk komposition, der indeholder Bupropion HCI som aktivt stof

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties